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Abstract
Aim: In this feasibility study we investigated whether magnetic resonance imaging (MRI) with ultrasmall superpar-
amagnetic iron oxide (USPIO) can be used to identify regional and distant lymph nodes, including mediastinal and
celiac lymph node metastases in patients with oesophageal cancer.
Patients and methods: Ten patients with a potentially curative resectable cancer of the oesophagus were eligible for this
study. All patients included in the study had positive lymph nodes on conventional staging (including endoscopic
ultrasound, computed tomography and fluorodeoxyglucose-positron emission tomography). Nine patients underwent
MRIþUSPIO before surgery. Results were restricted to those patients who had both MRIþUSPIO and histological
examination. Results were compared with conventional staging and histopathologic findings.
Results: One patient was excluded due to expired study time. Five out of 9 patients underwent an exploration; in
1 patient prior to surgery MRIþUSPIO diagnosed liver metastases and in 3 patients an oesophageal resection was
performed. USPIO uptake in mediastinal lymph nodes was seen in 6 out of 9 patients; in 3 patients non-malignant
nodes were not visible. In total, 9 lymph node stations (of 6 patients) were separately analysed; 7 lymph node stations
were assessed as positive (N1) on MRIþUSPIO compared with 9 by conventional staging. According to histology
findings, there was one false-positive and one false-negative result in MRIþUSPIO. Also, conventional staging
modalities had one false-positive and one false-negative result. MRIþUSPIO had surplus value in one patient.
Not all lymph node stations could be compared due to unforeseen explorations. No adverse effects occurred after
USPIO infusion.
Conclusion: MRIþUSPIO identified the majority of mediastinal and celiac (suspect) lymph nodes in 9 patients
with oesophageal cancer. MRIþUSPIO could have an additional value in loco-regional staging; however, more
supplementary research is needed.
Keywords: oesophageal cancer; oesophagectomy; lymph node staging; ultrasmall superparamagnetic iron oxide (USPIO)-enhanced
magnetic resonance imaging (MRI).
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Introduction
An oesophageal resection for cancer is a major surgical
procedure associated with substantial peri-operative mor-
bidity (4050%) and mortality (215%)[1]. To determine
resectability in these tumours, adequate staging is essen-
tial, selecting only those patients who may benefit from
curative surgery[2,3]. Anatomical staging of these tumours
is usually performed in specialized institutes by endo-
scopic ultrasonography (EUS) plus fine-needle aspiration
(FNA) and computed tomography (CT) of the neck,
chest and abdomen[4]. However, traditional methods
for staging oesophageal cancer have limited sensitivity
and specificity. The incidence of missed distant lymph
node metastases prior to surgery not detected by conven-
tional imaging techniques is relatively high (1038%)[5,6].
Because anatomic imaging (CT, EUSþFNA) primarily
depends on the size of lymph nodes, frequently found
nodal metastases that are not enlarged are missed[7].
Furthermore, FNA can be very difficult to perform due
to unreachable lymph nodes or indistinct determination
of malignant nodes by EUS. Moreover, suspected lymph
nodes can be situated behind the primary tumour, so the
endoscopist has to puncture through the tumour to reach
the lymph node, with a high chance of false-positive
results. Therefore, better pre-operative staging is war-
ranted to prevent unnecessary explorative surgery in
this group of patients.
18F-fluoro-2-deoxy-D-glucose-positron emission tomo-
graphy (FDG-PET) has become a conventional pre-
operative staging modality for oesophageal cancer.
However, it is primarily used for the detection of distant
lymph node adenopathy and haematogenous metastases
(M1a/b) because of the low sensitivity (3050%)
for detection of local malignant lymph nodes[8,9].
Moreover, false-positive results may occur due to an
increased glucose metabolism in benign lesions[10]. The
drawback of FDG-PET is the lack of anatomical infor-
mation on the metastases detected, which can be partially
solved by using the combination of PET/CT[11].
Recently, magnetic resonance (MR) imaging with
ultrasmall superparamagnetic iron oxide (USPIO) is gain-
ing acceptance as a non-invasive method for the detection
of lymph node metastases in several tumours[
1219]. MR
provides images with excellent anatomical detail and soft
tissue contrast but at the same time is relatively insensi-
tive to lymph node metastases due to the limited sensi-
tivity of current node size criteria in differentiating
benign from malignant nodes[12]. However, the MR
results can be improved by using a superparamagnetic
contrast such as USPIO[20,21]. USPIO acts as a negative
contrast agent and therefore normal functioning lymph
nodes can be distinguished from lymph node metastases
on the basis of magnetic resonance signal characteristics,
independent of nodal size[16,17,21,22].
High sensitivities ranging from 81 to 100%, specificities
ranging from 77 to 98% and accuracies ranging from
86 to 95% have been reported for MRþUSPIO lymph
node staging for different types of tumours[
1215,2224].
These encouraging results warrant further investigation
in oesophageal cancer with its early and unpredictable
pattern of nodal spread.
This feasibility study was designed to assess the value
of MR enhanced with USPIO for the detection of lymph
nodes and staging of nodal metastases in oesophageal
cancer. The main objective was to investigate whether
USPIO can be used to detect both regional and distant
lymph nodes and nodal metastases, in patients with
oesophageal cancer, and, furthermore, whether MR
alone or enhanced with USPIO could visualize these
lymph node metastases, including mediastinal and
celiac lymph nodal metastases. The results of MR with
USPIO were compared with the conventional staging
results (EUS, CT, FDG-PET) and with routine histologi-
cal findings as the gold standard.
Patients and methods
Patients
Ten patients with potentially resectable cancer of the
oesophagus or gastro-oesophageal junction were eligible
for this study. All patients were selected on clear med-
iastinal and/or celiac nodal involvement (N1 or M1a) as
determined by conventional staging modalities (EUS,
CT, PET), to ensure comparison of normal nodes and
nodal metastases for MRþUSPIO with other staging
procedures and pathology. CT and EUS assessed
lymph nodes on size and morphology. Nodes with a
size410mm and/or irregular shape were suspected for
malignancy, nodes with a size of 510mm were scored
as possible malignancy. Staging on PET was performed
by standard staging protocols for standard uptake value
and based on the experience of the nuclear medicine
physician.
Patients were able to tolerate MRI, USPIO infusion
and oesophagectomy. MRI and USPIO infusion was per-
formed after evaluation of conventional staging modal-
ities and approximately 1 week before surgery. Exclusion
criteria were: known allergies to dextran or iron-contain-
ing compounds, age 518 years, pregnancy, previous
treatment for oesophageal cancer, claustrophobia, aneu-
rysm clips, pacemakers or artificial heart valves.
One patient had to be excluded due to expired study
time of the USPIO contrast. In the remaining 9 patients
we evaluated the impact of USPIO-enhanced MRI in
detecting lymph node metastases in oesophageal




The lymphotropic superparamagnetic nanoparticles used
in this study were a monocrystalline iron oxide made of
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biodegradable particles, dextran and sodium citrate
(Sinerem, Guerbet, Paris, France)[25]. The nanoparticles
are composed of an iron oxide crystalline core 5 nm in
diameter and are covered with low molecular weight dex-
tran. The lyophilized iron oxide powder was reconstituted
in normal saline (10ml) and injected in 100ml saline
fluid. Based on the results of a dose-ranging study, the
solution was infused intravenously, through a filter, at a
rate of 4ml/min over a period of approximately 30min,
2436 hours before MR, at a dose of 2.6mg of iron per
kilogram of body weight (0.13ml/kg)[26].
After intravenous administration, USPIO particles
reach lymph nodes by two distinct pathways (Fig. 1).
The major pathway is that of direct transcapillary passage
through high endothelial venules within individual lymph
nodes. Once within the nodal parenchyma, phagocytic
cells of the mononuclear phagocyte system engulf the
particles. The second pathway is through nonselective
endothelial transcytosis across permeable capillaries
throughout the body into the interstitium. USPIO parti-
cles are subsequently taken up from the interstitium by
lymphatic vessels and transported to regional lymph
nodes[20,27].
A lymph node with normal phagocytic function takes
up a substantial amount of USPIO and therefore mark-
edly reduces the signal intensity following intravenous
administration of iron oxide agents secondary to the
magnetic susceptibility and T2* shortening effects of
the iron oxide particles[12]. In metastatic lymph nodes,
tumour cells replace the normal cells. This results in a
decrease in the number of macrophages and can there-
fore result in a decrease in the uptake of a lymph node-
specific tracer and maintains relatively high signal
intensity[28].
The most frequently reported adverse events in the lit-
erature are headache, back pain, vasodilatation and urti-
caria, each of which occur in 6% of patients[
12,13,28]. No
serious adverse events have been reported. Possible
adverse effects were examined verbally and clinically
during USPIO infusion and 24 hours after infusion.
During the infusion of USPIO, a physician was present
to watch over the process and detect possible adverse
effects.
Magnetic resonance (MR)
MRI was performed with a 1.5 T unit (Siemens Sonata).
T1, T2 and T2* (gradient echo) transverse and coronal
images of the cervical region and thorax and upper abdo-
men were obtained before and 2436 hours after the
intravenous administration of USPIO. MRI sequence
parameters are listed in Table 1. After surgery, the resec-
tion specimens, or in the case of non-resectability excised
lymph nodes, were fixated on a grid with anatomical
Figure 1 Schematic pathway of USPIO uptake in lymph nodes: reproduced with permission from Harisinghani et al.
NEJM 2003[13].
Detection of lymph node metastases with USPIO-enhanced MRI 21
landmarks, and scanned ex vivo with T2* sequences.
These results were compared with MRIþUSPIO in vivo.
Image analysis
The MR images were evaluated independently by an
experienced MR radiologist who was blinded for out-
come of conventional staging modalities, surgical out-
come and histopathalogic examination. These
MRþUSPIO results were compared with the histopatho-
logical findings of the pathologist.
In MRI with lymphotropic superparamagnetic nano-
particles, nodes were considered malignant when one
of the following criteria were present: a decrease in
signal intensity of more than 30% on T2-weighted fast
spinecho or gradient-echo sequences; a heterogeneous
signal (giving the entire node a mottled appearance), dis-
crete focal defects (isolated islands of high signal inten-
sity), or both; and nodes with a central area of
hyperintensity (excluding a fatty hilum) but a peripheral
decrease in signal intensity (Fig. 2)[13]. The signal-to-
noise ratios of lymph nodes were determined by manually
marking regions of interest over lymph nodes on different
scans and pulse sequences. Diagnostic procedures were
evaluated by histopathological examination of each
lymph node according to the fixated anatomical localiza-
tion (Fig. 3). Histopathology was considered to be the
gold standard.
Surgery
In the 9 eligible patients, the peritoneal cavity was first
explored to exclude metastatic disease. In the case of
peritoneal carcinomatosis, hepatic metastases and bulky
nodal involvement of42 cm within 1 cm of the celiac
region (M1), resection was not performed after histolo-
gical confirmation (frozen section). In these cases we
attempted to remove the relevant lymph nodes on the
basis of MRI results. If the above-mentioned nodes
were not involved, a radical resection with curative
intent was performed. Standard oesophageal resection
consisted of either a distal oesophagus/cardia resection
through a left thoraco-laparotomy with intrathoracic ana-
stomoses or a subtotal oesophageal resection through a
right thoraco-mid-laparotomy with cervical anastomoses.
Both were combined with a two-field lymphadenectomy
of mediastinal nodes and abdominal nodes, including
those at the celiac trunk, upper border of the pancreas
and para-aortic region. Based on the results of the
USPIO-enhanced MRI, suspected lymph nodes were
included.
To match the MR imaging to the ex vivo lymph nodes,
a fixation method was used to interpret the lymph node
groups according to Fig. 3. The resection specimen was
pinned in a polycarbonate box with a grid and a trans-
parent cover to keep anatomical survey possible (Fig. 4).
On this box, the locations of (suspected) nodes were
carefully marked and described by the surgeon to make
the comparison with all MR images (MRI, MRIþUSPIO
and MRI of ex vivo resection specimen) and pathology.
Histology
All independent lymph nodes found during pathology
were marked by their anatomical position and compared
by individual lymph nodes on MR. Lymph nodes were
examined histologically according to the standard histo-
logical procedures. Adenocarcinoma seen on hematoxy-
lin and eosin staining was, in all cases, confirmed by
ceratin staining (immunohistochemical analysis).
Data analysis
Due to the unforeseen explorations, evaluation of
the final results was restricted to those patients who
had both MRIþUSPIO and histological examination.
For this feasibility study, only descriptive and correlation
statistics were used. The results of this feasibility study
will provide enough information to assess the potential
use of USPIO-enhanced MR for detecting and staging
Table 1 MRI sequence parameters
Cervical/thorax:
T2-TSE-tra-fs T2-Fl2D-tra-we T1-MPRage-tra-fs T2-Fl2D-cor-we
TR 5100 327 1840 236
TE 104 4,76 4,38 4,76
FOV 250 280 280 350
Slice 5 5 1,7 5
Matrix 320*288 320*288 256*256 320*288
Voxel 0,9*0,8*5 1*0,9*5 1,1*1,1*1,7 1,2*1,1*5
Thorax/abdomen:
T2-TSE-tra-FrBr T2-fl2D-tra-FrBr T1-VIBE-tra-fs-bh
TR 1490 1530 4,78
TE 87 4,08 2,26
FOV 360 360 350
Slice 5 5 2
Matrix 384*269 256*192 256
*
166,5
Voxel 1,3*0,9*5 1,9*1,4*5 2,1*1,4*2
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lymph node metastases in oesophageal cancer patients in
future clinical studies.
Medical ethics
This study was conducted according to the principles of
the Declaration of Helsinki 1975, and its subsequent
revisions, and in accordance with the principles of
Good Clinical Practice and the Medical Research
Involving Human Subjects Acts. The study was approved
by the Medical Ethical Committee of our university hos-
pital. Patients were informed about the purpose and
hazards of the study, both orally and in writing, and
gave their written informed consent.
Results
All 9 patients were staged pre-operatively as N1 and/
or M1a oesophageal adenocarcinoma with conventional
staging modalities (including EUS, CT and FDG-PET).
Patient characteristics are summarized in Table 2.
Six out of 9 patients had no resection due to extensive
lymph node involvement or unexpected distant
metastases.
One patient appeared to have liver metastases which
were observed on the pre-operative MRIþUSPIO, and
which was confirmed by additional abdominal ultrasono-
graphy. Subsequently, percutaneous biopsies revealed
metastases (adenocarcinoma). This patient was therefore
excluded from surgery.
During the operation, 1 patient appeared to have his-
tologically proven pleural metastases, another patient had
a T4 tumour with ingrowth at the left main bronchus.
Another patient had unforeseen growth of the tumour
into the wall of the abdominal aorta and diaphragm,
with suspected lymph nodes in the hepatoduodenal liga-
ment. Three patients had previously undetected liver
Figure 2 Schematic diagnostic guidelines for USPIO-enhanced MR imaging. Nodes are considered malignant when one
of the following criteria are present: a decrease in signal intensity of less than 30% on T2-weighted fast spin-echo or
gradient-echo sequences after the administration of USPIO; a heterogeneous signal (giving the entire node a mottled
appearance), discrete focal defects (isolated islands of high signal intensity), or both; and nodes with a central area of
hyperintensity (excluding a fatty hilum) but a peripheral decrease in signal intensity.
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metastases; two small lesions (50.5 cm) were histologi-
cally proven during exploration. During two explorative
procedures lymph node samples were taken of the
MRIþUSPIO suspected lymph nodes for histological
conformation. The remaining 3 patients underwent a
standard oesophageal resection with a post-operative con-
trol MRI of the resected specimen followed by histo-
pathological examination.
Figure 4 Polycarbonate fixation box with cover and grid to keep the in vivo anatomical position of the resection
specimen for ex vivo MRI and histological examination intact. Remarks, number of lymph nodes and anatomical location
were marked on the transparent cover, above the fixated specimen. Separate lymph nodes were fixated at the side with
exact described anatomical location by the surgeon.
Figure 3 Anatomical localization of lymph node stations. According to the American Joint Committee on Cancer
(AJCC), Cancer Staging Manual, Sixth edition (2002).
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Because of the five explorations and 1 patient with liver
metastases prior to surgery, histology was not acquired
for interpretation of two MRIþUSPIO diagnosed lymph
node stations. Therefore, no outcome can be given
between the comparison of standard modalities and
MRIþUSPIO in these two lymph node stations. In
other explorations, lymph node stations suspected by
conventional and MRIþUSPIO staging were (partially)
dissected to obtain histology.
Identification of lymph nodes on MRI alone was not
comparable with conventional staging, especially in small
and irregular nodes on CT. These small nodes were iden-
tified after USPIO infusion with T2* MRI, although spa-
tial resolution is slightly less than on CT. USPIO uptake
was seen in 6 out of 9 patients in several abdominal and
mediastinal lymph node stations (Fig. 5ac and
Fig. 6a,b); in 3 patients non-malignant nodes were not
visible with USPIO. Out of the 6 patients with USPIO
uptake, in total 9 lymph node stations were analysed.
These 9 lymph node stations were compared with con-
ventional staging modalities whereby histological exami-
nation was the gold standard. The following stations were
assessed as positive (N1): 7 lymph node stations on













Squamous cell carcinoma 0
Figure 5 (A) Pre-enhanced MR image of patient 02 (T2* without USPIO); indicated lymph node (·-----); (B) USPIO-
enhanced MR imaging T2* of patient 02; no USPIO uptake in indicated (·-----) lymph node which corresponds with
Fig. 5A. Other lymph nodes in this series demonstrated USPIO uptake. (C) USPIO-enhanced MR T2* image of
resection specimen (distal oesophagus and part of the cardia with fatty tissue and lymph nodes along the minor curva-
ture) of patient 02 with corresponding lymph node as in Fig. 5AþB (·-----). Note the USPIO uptake in marked histology
proven negative lymph node (·- - - -) and no USPIO uptake in histology proven positive lymph node (·-----).
Detection of lymph node metastases with USPIO-enhanced MRI 25
MRIþUSPIO and 9 stations on conventional staging
modalities (Table 3).
Histology was only available in 7 lymph node stations
due to the unforeseen explorations. Five of these 7
(83.3%) lymph node stations were proven positive (N1)
by histology findings (Fig. 7).
For conventional staging, there was one false-positive
and one false-negative result according to histology. For
MRIþUSPIO there was also one false-positive and one
false-negative finding. One of the false-positive lymph
nodes, according to histology, was positive on
MRIþUSPIO as well as conventional staging. One sta-
tion was missed by all conventional staging modalities
and positive on MRIþUSPIO, which was confirmed
by histology examination.
In comparison with MRIþUSPIO in vivo and post-
operative MRI of the resected specimen, more negative
lymph nodes were seen ex vivo on the MRI. There was no
increase in positive lymph nodes seen on MRIþUSPIO
ex vivo. Furthermore, the number of histology-proven pos-
itive lymph nodes did not differ.
All patients received the full dose USPIO and com-
pleted the entire study. The average total MRI examina-
tion time of 1 hour was well tolerated in all cases. No
adverse effects were encountered in the 9 patients
included in the study, either during or after infusion
of USPIO. The patients experienced no greater burden
than with other staging modalities.












01 17 þ þ þ P P exploration
8 þ  #
02 8 þ þ  FP FP
16/17 þ þ þ P P
03 8/9 þ þ þ P P exploration
04 8 þ  þ P FN
17  þ þ FN P
06 16/17 þ þ # exploration
08 7/8 þ þ þ P P
USPIO: Patient study number (0109). Lymph node station: number of lymph node station(s) according to Fig. 3. Conventional staging: staging
based on conventional staging modalities (CT/PET/EUS) and multidisciplinary consultation. MRI USPIO staging: staging of related lymph
nodes according to USPIO uptake (þ¼ no USPIO uptake in corresponding lymph node, suspect for malignancy). Pathology: staging based on
histology findings of corresponding lymph node (gold standard) #¼ no histology available. Outcome conventional staging P¼ positive finding,
FP¼ false-positive, FN¼ false-negative. Outcome USPIO: P¼ positive finding, FP¼ false-positive, FN¼ false-negative.
Figure 6 (A) Pre-enhanced T2* image of patient 08.
Note two indicated lymph nodes; (B) USPIO-enhanced
T2* image of patient 08. Note two indicated lymph
nodes without USPIO uptake which were proven positive
on histopathologic findings.
Figure 7 Partial lymph node with metastatic adenocarci-
noma tissue, proven by ker Ae1/3 immunohistochemical
staining (black staining ) of patient 02 with correspond-
ing MRþUSPIO suspected malignant lymph node.
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Discussion
In this feasibility study, USPIO uptake was seen in 6 out
of 9 eligible patients. In 5 patients lymph node status was
positive on conventional staging and MRIþUSPIO, and
was confirmed by histopathological examination.
MRIþUSPIO upstaged 1 patient according to standard
staging modalities. Due to the pre-operative selection on
nodal metastases, unfortunately only 3 patients under-
went a resection and histology was only acquired in 5
patients (7 lymph node stations) due to unforeseen exten-
sive cancer growth or metastases. This was the major
drawback of this study and therefore these results
might be an underestimation.
Identification of lymph nodes on MRI alone had
no additional value, especially in small nodes on CT.
These small nodes could be identified after USPIO
infusion with T2* MRI, although spatial resolution
is slightly less than on CT. No adverse effects were
found by the infusion of USPIO and patients
experienced no greater burden than with other staging
modalities.
All patients in this study had adenocarcinoma. It is
unclear if the same results for USPIO uptake would be
found in patients with squamous cell carcinoma. We
expect that there will be no difference in USPIO uptake
in the lymph nodes for squamous cell carcinoma, because
USPIO uptake is dependent on physical invasion of the
nodes and not on physiological behaviour of the tumour
cells. However, this question should be answered in forth-
coming studies.
In 5 out of 9 patients current staging modalities missed
local or distant metastases and resulted in a surgical
exploration; a complete comparison by conventional
modalities and USPIO-enhanced MRI could therefore
not be made. This stresses the importance of finding
new, adequate staging procedures and improving conven-
tional diagnostic modalities. MRI enhanced with USPIO
appears to be a good predictor of oesophageal lymph
node staging. There was avid USPIO uptake in the major-
ity of mediastinal and paragastric lymph nodes.
MRþUSPIO may have high potential value as a new
non-invasive staging modality in oesophageal cancer.
USPIO could be applied safely, is inexpensive in compar-
ison with EUS and PET and its technique (MRI) is
widely available. More research is needed to compare
MRIþUSPIO with current staging modalities and
therefore we propose a diagnostic accuracy study with
inclusion of all potentially curative patients on conven-
tional staging modalities to assess its accuracy and
efficacy.
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